ABSTRACT

INTRODUCTION: Hypercoagulable state contributing to thrombotic complications worsens COVID-19 severity and outcomes, while anticoagulation improves outcomes by alleviating hypercoagulability.

OBJECTIVES: Examine whether hemophilia, an inherent hypocoagulable condition, offers protection against COVID-19 severity and reduces VTE risk in persons with hemophilia (PwH).

PATIENTS/METHODS: A 1: 3 propensity score (PS) matched retrospective cohort study used national COVID-19 registry data (January 2020 through January 2022) to compare outcomes between 300 male PwH and 900 matched controls without hemophilia.

RESULTS: Analyses of PwH demonstrated known risk-factors (older age, heart failure, hypertension, cancer/malignancy, dementia, renal and liver disease) contributed to severe COVID-19 and/or 30-day-all-cause mortality. Non-CNS bleeding was an additional risk-factor for poor outcomes in PwH. Odds of developing VTE with COVID-19 in PwH were associated with pre-COVID VTE diagnosis (OR 51.9, 95% CI 12.8-266, p<0.001),<0.001)<0.001).<0.001)

CONCLUSION: After adjusting for patient characteristics/comorbidities, hemophilia increased bleeding risk with COVID-19 but did not protect against severe disease and VTE.

PMID:37182697 | PMC:PMC10181864 | DOI:10.1016/j.jtha.2023.04.040

14:29

PubMed articles on: Cancer & VTE/PE

Identification, characterization, and engineering of glycosylation in thrombolytics

Biotechnol Adv. 2023 May 12;66:108174. doi: 10.1016/j.biotechadv.2023.108174. Online ahead of print.